MedPath

A randomized, open-label clinical trial on the efficacy of blonanserin and olanzapine in patients with schizophrenia and dopamine supersensitivity psychosis

Phase 4
Conditions
Schizophrenia
Registration Number
JPRN-UMIN000017047
Lead Sponsor
Chiba University Hospital Clinical Research Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
61
Inclusion Criteria

Not provided

Exclusion Criteria

1)[Criteria for DSP] First episode schizophrenia 2)[Criteria for DSP] Unstable and continuous severe psychotic symptoms under antipsychotic treatment for more than 3 months 3))[Criteria for DSP] Deficit syndrome 4)Contraindication to blonanserin/olanzapine

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath